

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISORS OF THE SECOND SESSION OF THE SUPERVISORY BOARD

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Company held the employee representative conference on May 7, 2024, at which Ms. QIAO Weiwei and Ms. LIU Ping were re-elected as the employee representative supervisors (the “**Supervisor**”), and they will jointly form the second session of the supervisory board (the “**Supervisory Board**”) of the Company with shareholder representative Supervisors to be elected at the 2023 annual general meeting. The term of office of employee representative Supervisors is three years and shall take effect from the date of the election of the employee representative conference.

The biographies of Ms. QIAO Weiwei and Ms. LIU Ping are as follows:

Ms. QIAO Weiwei, aged 37, was appointed as a Supervisor on May 9, 2021 and was appointed as chairman of the Supervisory Board on September 16, 2022. Ms. Qiao has been serving as a manager of human resources and director of general manager’s office in our Company, as well as the deputy director of human resources of the Company since November 1, 2021. She is primarily responsible for overseeing the operations and financial affairs. Ms. Qiao has been serving as a supervisor in Wuhan Recbio Biotechnology Co., Ltd. (武漢瑞科生物技術有限公司), one subsidiary of our Company since September 2021. Ms. Qiao has been serving as a supervisor of Hangzhou Ruibaio Technology Company Limited (杭州瑞佰奧科技有限公司), a subsidiary of the Company since February 2023.

Prior to joining our Group, Ms. Qiao worked in Taizhou Xinchengyuan Biological Medicine Co., Ltd. (泰州新生源生物醫藥有限公司) from July 2009 to June 2018. Ms. Qiao worked at Wenzhou Biomedical Collaborative Innovation Center (溫州市生物醫藥協同創新中心) from June 2018 to December 2019. Ms. Qiao worked as a project performance managing expert in Beijing ABZYMO Biosciences Co., Ltd. (北京安百勝生物科技有限公司) from August 2020 to October 2020.

Ms. Qiao obtained her bachelor's degree in business administration from Nanjing University of Finance and Economics (南京財經大學) in the PRC in July 2014. Ms. Qiao has been qualified as National Certificate of Human Resource Managers II and III of PRC in April 2015 and July 2013, respectively. In September 2016, Ms. Qiao also obtained certification for completing the Advanced Seminar on the 13th Five-year Development Plan of Biopharmaceutical Industry of Jiangsu Province from Department of Human Resources and Social Security of Jiangsu Province. In May 2014, Ms. Qiao obtained certification for completing Taizhou's Enterprise Human Resource Manager Quality Improvement Training Course from Taizhou Human Resources and Social Security Department.

Ms. LIU Ping, aged 44, was elected as an employee representative Supervisor on June 30, 2022. Ms. Liu has successively served as a deputy manager, a manager of the comprehensive management department of the Company since November 2019. Ms. Liu served as the QA director of Gan & Lee Pharmaceuticals Co., Ltd. (甘李藥業有限公司) (the predecessor of Gan & Lee Pharmaceuticals Co., Ltd.) from January 2002 to August 2010. Ms. Liu served as the director of the quality department of Beijing Mabworks Biotech Co., Ltd. (北京天廣實生物技術股份有限公司) from September 2010 to April 2011. Ms. Liu served as the manager of the quality department of Beijing ABZYMO Biosciences Co., Ltd. from May 2011 to October 2019.

Ms. Liu graduated from Shenyang Pharmaceutical University (瀋陽藥科大學) in 2001, and from the Network School of Medical Education of Peking University (北京大學醫學網絡教育學院) in 2015, both majoring in pharmacy.

The Company will enter into supervisor service contracts with Ms. QIAO Weiwei and Ms. LIU Ping. Ms. QIAO Weiwei and Ms. LIU Ping will not receive remuneration as Supervisors from the Company, but they will continue to receive remuneration as employees during their terms of office unless otherwise specified in the Company's remuneration scheme for Supervisors.

Save as disclosed in this announcement, as of the date of this announcement, each of Ms. QIAO Weiwei and Ms. LIU Ping has confirmed that (1) she did not hold any directorships in any other listed companies in the past three years nor did she have any other major appointments or professional qualifications; (2) she did not hold any positions in the Company or any of its subsidiaries; (3) she did not have any relationship with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company or any of its subsidiaries; and (4) she did not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, the Board of the Company is not aware of other information on the appointment of Ms. QIAO Weiwei and Ms. LIU Ping which shall be disclosed pursuant to the requirements set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters in relation to the appointment of Ms. QIAO Weiwei and Ms. LIU Ping that need to be brought to the attention of the Company's shareholders.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. LIU Yong
Chairman

Jiangsu Province, the PRC, May 7, 2024

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Dr. CHEN Jianping, Mr. LI Bu and Ms. CHEN Qingqing as executive Directors, Dr. HONG Kunxue, Dr. ZHOU Hongbin, Dr. ZHANG Jiaxin and Mr. HU Houwei as non-executive Directors, and Mr. LIANG Guodong, Dr. XIA Lijun, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.